Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Regeneron Pharmaceuticals, Inc’s stock clocked out at $542.52, down -1.36% from its previous closing price of $550.0. In other words, the price has decreased by -$1.36 from its previous closing price. On the day, 1.31 million shares were traded. REGN stock price reached its highest trading level at $550.53 during the session, while it also had its lowest trading level at $541.5.
Ratios:
To gain a deeper understanding of REGN’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.02 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.88. For the most recent quarter (mrq), Quick Ratio is recorded 4.03 and its Current Ratio is at 4.93. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.09.
On May 30, 2025, Wells Fargo Downgraded its rating to Equal Weight which previously was Overweight but kept the price unchanged to $580.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on May 30, 2025, while the target price for the stock was maintained at $662.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 01 ’24 when McCourt Marion sold 1,000 shares for $844.61 per share. The transaction valued at 844,610 led to the insider holds 12,931 shares of the business.
MARION E MCCOURT bought 1,000 shares of REGN for $844,610 on Nov 01 ’24. On Oct 01 ’24, another insider, RYAN ARTHUR F, who serves as the Director of the company, sold 100 shares for $1048.78 each. As a result, the insider received 104,878 and left with 17,582 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, REGN now has a Market Capitalization of 58573172736 and an Enterprise Value of 49829785600. As of this moment, Regeneron’s Price-to-Earnings (P/E) ratio for their current fiscal year is 13.81, and their Forward P/E ratio for the next fiscal year is 13.99. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 11.60. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.16 while its Price-to-Book (P/B) ratio in mrq is 2.00. Its current Enterprise Value per Revenue stands at 3.538 whereas that against EBITDA is 11.145.
Stock Price History:
The Beta on a monthly basis for REGN is 0.33, which has changed by -0.49284875 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, REGN has reached a high of $1211.20, while it has fallen to a 52-week low of $476.49. The 50-Day Moving Average of the stock is -0.31%, while the 200-Day Moving Average is calculated to be -21.25%.
Shares Statistics:
It appears that REGN traded 1.31M shares on average per day over the past three months and 942550 shares per day over the past ten days. A total of 106.40M shares are outstanding, with a floating share count of 104.07M. Insiders hold about 3.61% of the company’s shares, while institutions hold 87.18% stake in the company. Shares short for REGN as of 1749772800 were 2031432 with a Short Ratio of 1.72, compared to 1747267200 on 2798186. Therefore, it implies a Short% of Shares Outstanding of 2031432 and a Short% of Float of 1.9800000000000002.
Dividends & Splits
With its trailing 12-month dividend rate of 0.88, REGN has a forward annual dividend rate of 1.76. Against a Trailing Annual Dividend Yield of 0.0016
